NCT05194111View on ClinicalTrials.gov

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Heart FailureHeart Dysfunction
Interventions
DRUG

Sacubitril-valsartan

Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).

DRUG

Valsartan

Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)

Trial Locations (1)

23298

RECRUITING

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER